Arcturus Therapeutics Holdings, Inc. (ARCT)
15.19
-0.98
(-6.06%)
USD |
NASDAQ |
Aug 28, 16:00
15.18
-0.01
(-0.07%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Gross Profit Margin (Quarterly) : 31.82% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.82% |
| March 31, 2026 | -7.87% |
| December 31, 2025 | 77.86% |
| September 30, 2025 | 94.35% |
| June 30, 2025 | 96.74% |
| March 31, 2025 | 96.86% |
| December 31, 2024 | 96.10% |
| September 30, 2024 | 97.68% |
| June 30, 2024 | 98.04% |
| March 31, 2024 | 97.23% |
| December 31, 2023 | 97.11% |
| September 30, 2023 | 98.16% |
| June 30, 2023 | 0.00% |
| March 31, 2023 | 0.00% |
| December 31, 2022 | 0.00% |
| September 30, 2022 | 0.00% |
| June 30, 2022 | 0.00% |
| March 31, 2022 | 0.00% |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 96.05% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 97.45% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Exelixis, Inc. | 96.71% |
| PTC Therapeutics, Inc. | 91.19% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -45.16% |
| Return on Assets | -35.00% |
| Return on Invested Capital | -40.29% |
| Profit Margin (Quarterly) | -2.70K% |
| Operating Margin (Quarterly) | -3.09K% |
| Return on Net Operating Assets | -262.8% |